ERBB3 and neoplasm: ADCs targeting HER2 and HER3, such as T-DXd and HER3-DXd, have demonstrated antitumor activity through in vitro and in vivo tumor models [6, 7, 26] as well as in patients with breast or lung cancer [27, 28].